Open Access

Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy

  • Authors:
    • Toru Aoyama
    • Keisuke Kazama
    • Yohei Miyagi
    • Masaaki Murakawa
    • Koichiro Yamaoku
    • Yosuke Atsumi
    • Manabu Shiozawa
    • Makoto Ueno
    • Manabu Morimoto
    • Takashi Oshima
    • Norio Yukawa
    • Takaki Yoshikawa
    • Yasushi Rino
    • Munetaka Masuda
    • Soichiro Morinaga
  • View Affiliations

  • Published online on: May 19, 2017     https://doi.org/10.3892/ol.2017.6220
  • Pages: 599-606
  • Copyright: © Aoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The predictive roles of human equilibrative nucleoside transporter 1 (hENT‑1) in patients who undergo curative resection and adjuvant chemotherapy with gemcitabine alone have not been established. The present study retrospectively analyzed the clinical data from 101 consecutive patients who underwent curative resection and who received gemcitabine adjuvant chemotherapy for the treatment of pancreatic cancer at Kanagawa Cancer Center (Yokohama, Japan) between 2005 and 2014. The associations between the hENT‑1 status and the survival and clinicopathological features of the patients were investigated. Of the 101 patients, 60 patients (59.4%) had high levels of hENT‑1 expression. A significant association was observed between hENT‑1 status and sex; however, for all the other clinicopathological parameters, including tumor and node stages, no differences were observed between the high and low hENT‑1 expression groups. The median follow‑up period of the present study was 67.3 months. Between the high and low hENT‑1 expression groups, there was a statistically significant difference in the 5‑year overall survival (OS) rates following surgery (20.6 and 8.9%, respectively; P=0.019). In addition, a significant difference was observed in the recurrence‑free survival (RFS) rates at 5 years following surgery (P=0.049). hENT‑1 status was one of the important predictive factors for OS and RFS in patients with pancreatic cancer who underwent curative resection followed by adjuvant chemotherapy with gemcitabine. Adjuvant chemotherapy with gemcitabine alone may be insufficient, particularly in patients with certain relevant risk factors.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Aoyama T, Kazama K, Miyagi Y, Murakawa M, Yamaoku K, Atsumi Y, Shiozawa M, Ueno M, Morimoto M, Oshima T, Oshima T, et al: Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. Oncol Lett 14: 599-606, 2017
APA
Aoyama, T., Kazama, K., Miyagi, Y., Murakawa, M., Yamaoku, K., Atsumi, Y. ... Morinaga, S. (2017). Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. Oncology Letters, 14, 599-606. https://doi.org/10.3892/ol.2017.6220
MLA
Aoyama, T., Kazama, K., Miyagi, Y., Murakawa, M., Yamaoku, K., Atsumi, Y., Shiozawa, M., Ueno, M., Morimoto, M., Oshima, T., Yukawa, N., Yoshikawa, T., Rino, Y., Masuda, M., Morinaga, S."Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy". Oncology Letters 14.1 (2017): 599-606.
Chicago
Aoyama, T., Kazama, K., Miyagi, Y., Murakawa, M., Yamaoku, K., Atsumi, Y., Shiozawa, M., Ueno, M., Morimoto, M., Oshima, T., Yukawa, N., Yoshikawa, T., Rino, Y., Masuda, M., Morinaga, S."Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy". Oncology Letters 14, no. 1 (2017): 599-606. https://doi.org/10.3892/ol.2017.6220